Cetuximab biosimilar - BioXpress Therapeutics

Drug Profile

Cetuximab biosimilar - BioXpress Therapeutics

Latest Information Update: 19 Aug 2013

Price : $50

At a glance

  • Originator BioXpress Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Head and neck cancer

Most Recent Events

  • 15 Aug 2013 Preclinical trials in Head and neck cancer in Switzerland (IV)
  • 15 Aug 2013 Preclinical trials in Colorectal cancer in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top